The Financialization of U.S. Public Pensions, 1945-1974

Vanatta, Sean H.

doi:10.2139/ssrn.4271045

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] Nowadays, disease management involves pain medication with nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics to relieve the symptoms, with joint replacement surgery the final stage of treatment. [4] However, the guidelines from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) encourage the development of effective disease-modifying osteoarthritis drugs (DMOADs). [5] DMOADs are drugs that modify the underlying OA pathophysiology to prevent or reduce long-term disability and offer potential symptomatic relief.…”

Section: Introductionmentioning

confidence: 99%

Phage Display Identified Peptide with Selectivity for Human Osteoarthritic Chondrocytes

Martins,

Canadas,

Pereira

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Osteoarthritis (OA) is one of the most common joint disorders in western populations, affecting millions of people worldwide and with a rising incidence as life expectancy continues to increase. Current therapies for OA management fail to halt the progressive degradation of articular cartilage, urging the need for more effective therapies to improve function and enhance quality of life. Through phage display technology, biopanning on a heterogenous chondrocyte population isolated from six different OA donors, and using a random 12‐amino acid peptide phage library, a cell‐binding peptide selective for human OA chondrocytes (GFQMISNNVYMR) is identified. A two‐fold increase in fluorescence intensity is observed for OA chondrocytes, compared to normal chondrocytes, when cells were incubated with the identified peptide conjugated to a fluorescent label, being selectively internalized by OA cells. The identified peptide can be further modified and exploited for developing early diagnostic of OA and/or improve drug delivery to target cells through peptide‐drug conjugates.This article is protected by copyright. All rights reserved

show abstract

Section: Introductionmentioning

confidence: 99%